-+ 0.00%
-+ 0.00%
-+ 0.00%

Assembly Bio reports positive Phase 1a safety, target engagement data for ABI-6250 NTCP inhibitor

PUBT·10/05/2026 14:03:33
Listen to the news
Assembly Bio reports positive Phase 1a safety, target engagement data for ABI-6250 NTCP inhibitor
  • Assembly Biosciences set two AASLD Liver Meeting 2026 poster presentations for ABI-6250 Phase 1a data on November 7, 2026.
  • Early-stage results showed the oral NTCP inhibitor was well tolerated in healthy participants with no serious adverse events reported.
  • Pharmacodynamic findings indicated target engagement, supporting plans to move ABI-6250 into Phase 2 development.
  • Phase 2 start is slated for Q4 2026 in chronic hepatitis delta virus infection.
  • A separate Phase 2 program in cholestatic liver diseases is planned for Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051000PRIMZONEFULLFEED9839048) on October 05, 2026, and is solely responsible for the information contained therein.